Cost-effectiveness analysis in oncology

Annals of Oncology

Volumn 9, Issue 5, 1998, Pages 475-482

  Earle, C C ^a,b   Coyle, D ^a,c,d   Evans, W K ^a,d  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b Societe canadienne du cancer   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Cancer; Cost; Cost analysis; Cost effectiveness; Health economics; Pharmacoeconomics

Indexed keywords

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; MEDICAL DECISION MAKING; ONCOLOGY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW;

COST-BENEFIT ANALYSIS; DECISION MAKING; ECONOMICS, MEDICAL; ECONOMICS, PHARMACEUTICAL; HEALTH CARE COSTS; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS;

EID: 0031839389     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008292128615     Document Type: Review

References (41)

1. Ontario Ministry of Health. Guidelines for preparation of economic analysis in submission to drug programs branch for listing in the Ontario Benefit Formulary/Comparative Drug Index. 1991 (Abstr).
2. Commonwealth of Australia. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: Including submissions involving economic analyses. 1992 (Abstr).
3. Grunfeld E, Glossop R, Mc Dowell I, Danbrook C. Caring for elderly people at home: The consequences to caregivers. Can Med Assoc J 1997; 157: 1101-6.
4. Eddy RJ. Cost-effectiveness of CT scanning compared with mediastinoscopy in the preoperative staging of lung cancer. J Can Assoc Radiol 1989; 40: 189-93
5. Houston BA,Griffith JE,Sanders JA et al. Staging of lung cancer. A cost-effectiveness analysis. Am J Clin Oncol (CCT) 1985; 8: 224-60.
6. Kesteloot K, Dutreix A, Scheuren Ev. Quality assurance in radiotherapy economic criteria to support decision making. International J Tech Assess Health Care 1993; 9: 274-85.
7. Kesteloot K, Dutreix A, Van der Scheuren E. A model for calculating the costs of in vivo dosimetry and portal imaging in radiotherapy departments. Radiother Oncol 1993; 28: 108-17.
8. Weltens C, Desteloot G, Vandevelde R, Van den Bogaert W. Comparison of plastic and orfit masks for patient head fixation during radiotherapy: precision and costs, Int J Radial Oncol Biol Phys 1995.
9. Evans WK, Burpee C, Skinn B et al. An evaluation of the costs of outpatient chemotherapy administration for small cell lung cancer. Can J Oncol 1993; 3: 225-32.
10. Williams C, Coyle D, Gray A et al. European School of Oncology advisory report to the Commission of the European Communities for the 'Europe Against Cancer Programme'cost-effectiveness in cancer care. Eur J Cancer 1995; 31A: 1410-24.
11. Gudex C, Kind P, The QALY Toolkit. Centre for Health Economies Discussion Paper 38, 1988 (Abstr).
12. Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Tech Assess Health Care 1989; 5: 559-75.
13. Goldhirsch A, Gelber RD, Simes RJ et al. Costs and benefits of adjuvant therapy in breast cancer: A quality-adjusted survival analysis. J Clin Oncol 1989; 7: 36-44.
14. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. JAMA 1996; 276: 1339-41.
15. Williams A. The cost benefit approach. British Medical Bulletin 1974; 249: 326-9.
16. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. In Anonymous-Oxford: OUP 1987.
17. Maynard A. The design of future cost benefit studies. Am Heart J 1990; 119: 761-5.
18. Drummond MK, Richardson WS, O'Brien BJ et al. Users'guides to the medical literature XIII. How to use an article on economic analysis of clinical practice A. Are the results of the study valid? JAMA 1997; 277: 1552-7.
19. O'Brien BJ, Heyland D, Richardson WS et al. Users'guides to the medical literature XIII. How to use an article on economic analysis of clinical practice B. What are the results and will they help me in caring for my patients? JAMA 1997; 277: 1802-6.
20. Evans WK, Will BP, Berthelot J, Wolfson MC. Estimating the cost of lung cancer diagnosis and treatment in Canada: The POHEM model. Can J Oncol 1995; 5: 408-19.
21. Jaakkimainen L, Goodwin PJ, Pater J. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in non-small cell lung cancer. J Clin Oncol 1990; 8: 1301-9.
22. Koopmanschap MA, Rutten FFH. Indirect costs in economic studies. Confronting the confusion. Pharmacoeconomics 1993; 4: 446-54.
23. Hayman J, Weeks J, Mauch P. Economic analyses in health care: an introduction to the methodology with an emphasis on radiation therapy, Int J Radiat Oncol Biol Phys 1996; 35: 827-41.
24. Finkler SA. The distinction between costs and charges. Ann Intern Med 1982; 96: 102-9.
25. Torrance GW, Blaker D, Detsky A et al. Canadian guidelines for economic evaluation of pharmaceuticuls. Pharmacoeconomics 1996; 9: 535-59.
26. Drummond MF, Coyle D. Assessing the economic value of antihypertensive medicines. J Hum Hypertens 1992; 6: 495-501.
27. Parsonage M, Neuberger H. Discounting and health benefits. Health Economics 1992; 1: 71-9.
28. Coyle D, Tolley K. Discounting of health benefits in the pharmacoeconomic analysis of drug therapies: An issue for debate? Pharmacoecononmics 1992; 2: 153-62.
29. Cairns J. Discounting and health benefits: Another perspective. Health Economics 1992; 1: 76-9.
30. Sheldon TA. Discounting in health-care decision-making time for a change. J Public Health Med 1992; 14: 250-6.
31. Fayers PM, Hand DJ. Generalisation from phase III clinical trials: survival, quality of life, and health economics. Lancet 1997; 350: 1025-7.
32. Laupacis A, Feeny D, Detsky A, Tugwell P. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146: 473-81.
33. Williams AH. Economics of coronary artery bypass grafting. BMJ 1985; 291: 326-9.
34. Maynard A. Developing the health care market. Economic J 1990; 101: 1277-86.
35. Schulman KA, Lynn LA, Click HA, Eisenberg JM. Cost-effectiveness of low-dose zidovudine therapy for asymptomatic patients with human deficiency virus (HIV) infection. Ann Intern Med 1991; 114: 798-802.
36. Smith TJ, Hillner BE, Desch CE. Efficacy and cost-effectiveness of cancer treatment: Rational allocation of resources based on decision analysis. J Natl Cancer Inst 1993; 85: 1460-74.
37. Drummond MF, Torrance GW, Mason J. Cost-effectiveness league tables: more harm than good? Soc Sci Med 1993; 37: 33-40.
38. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313: 275-83.
39. Gerard K. Cost-utility in practice: A policy maker's guide to the state of the art. Health Policy 1992; 21: 249-79.
40. Coyle D. Statistical analysis in pharmacoeconomic studies. A review of current issues and standards. Pharmacoeconomics 1996; 9: 506-16.
41. Evans WK, Chevalier T. The cost-effectiveness of Navelbine alone or in combination with cisplatin in comparison to standard therapies in stage IV non-small cell lung cancer. Eur J Cancer 1996; 32A: 2249-55.